In addition, the BRAF inhibitors in combination with MEK inhibitors have been established as the standard adjuvant and neoadjuvant therapy for malignant melanoma with BRAF V600E mutations based on high-level clinical evidence (16, 17). The gene discussed is MAP2K7; the disease is melanoma.